$715 Million in 48 Hours: The Two Bets Reshaping Biotech

The round was reportedly heavily oversubscribed. New investors included Bain Capital Ventures, Battery Ventures, and Baillie Gifford, while existing backers like OpenAI and Thrive Capital doubled down. When both tech VCs and life science specialists are fighting for allocation, it tells you something about where the market thinks this company is headed.

Radioactive Bullets for Cancer

If Chai represents biotech's software layer, AdvanCell represents something far more physical: building tiny radioactive missiles that hunt down cancer cells.

AdvanCell develops targeted alpha therapies (TATs), a next-generation form of radiopharmaceutical. The basic idea is elegant. You attach a radioactive isotope to a molecule that seeks out cancer cells, and when it arrives, the isotope releases alpha particles that shred the tumor's DNA. It's like a guided missile versus a carpet bomb; the radiation goes exactly where you want it.

AdvanCell's secret weapon is Lead-212 (Pb-212), an isotope with a short half-life of about 10.6 hours. That's long enough to do damage to tumors but short enough to limit collateral harm to healthy tissue. The company's lead drug, ADVC001, targets PSMA-positive metastatic prostate cancer and is currently in Phase 2 trials, with the new funding earmarked to push it toward Phase 3.

The $315 million Series D was co-led by Ally Bridge Group and Alpha Wave Global. But the names that really matter are the strategic investors: Eli Lilly and Sanofi Ventures both participated. When two of the world's largest pharma companies invest in your private round, it's not just capital; it's a signal that they might want to buy what you're building someday.

AdvanCell also has a collaboration with Lilly to co-develop additional alpha therapies across multiple cancer types, further cementing the strategic relationship.

Beyond ADVC001, the company has five assets in discovery and two in preclinical development, all built on the same Pb-212 platform. Critically, AdvanCell is vertically integrated: it controls its own isotope supply chain and manufacturing infrastructure, with facilities in Australia and expanding capacity in the U.S. In a world where isotope shortages are the biggest bottleneck for radiopharmaceutical development, owning your supply chain is like owning the oil refinery, not just the gas station.

What $715 Million Tells Us About Where Biotech Is Headed

Zoom out and these two rounds paint a clear picture of 2026's venture capital landscape.

First, capital is concentrating, not disappearing. At least 68 biotech companies raised over $9.1 billion in the first half of 2026, but roughly 76% of that capital flowed into rounds of $100 million or more. The rich are getting richer. If you're a category leader with real data or real revenue, money is abundant. If you're not, good luck.

Second, AI-biotech valuations have entered a new tier. Isomorphic Labs (backed by Alphabet) raised a staggering $2.1 billion Series B earlier this year, the largest single private financing round in AI drug discovery history. Chai's $400 million at a $3.8 billion valuation fits the pattern. The premium for AI-biotech is real, and investors are paying it willingly.

Third, radiopharmaceuticals are no longer a niche. The modality has graduated from academic curiosity to a core oncology investment thesis. Alpha-emitting therapies like AdvanCell's represent a potential leap beyond the beta-emitting radiotherapeutics (think Novartis's Pluvicto) that opened the category. Investors see isotope supply as the key moat, which is why AdvanCell's vertical integration story resonates so strongly.

Finally, notice who's showing up in these syndicates. Crossover funds like Baillie Gifford and T. Rowe Price are writing large checks alongside traditional biotech VCs. Strategic pharma investors (Lilly, Sanofi, OpenAI in a different context) are using equity positions to secure access to platforms they may eventually want to acquire or expand partnerships with. The line between venture investing and business development has never been blurrier.

The Billion-Dollar Question

The optimistic read: these rounds validate that AI drug design and targeted radiotherapies are maturing from "promising" to "proven." Chai has paying customers at the biggest pharma companies on earth. AdvanCell has clinical data and strategic partners lining up.

The cautious read: tripling your valuation in seven months (Chai) or raising $315 million for a Phase 2 asset (AdvanCell) requires everything to go right. AI-designed molecules still need to prove they improve clinical success rates, not just speed up early discovery. And manufacturing radioactive isotopes at commercial scale is an engineering challenge that money alone can't solve.

But for now, investors are voting with their checkbooks. Two mega-rounds, two days, $715 million, and a very clear signal about where biotech's next chapter is being written.

GSK Just Lit $700 Million on Fire in the Neuroscience Graveyard

GSK walked away from a $2.2 billion neuroscience deal with Alector after both antibody drugs flopped in clinical trials. The $700 million already spent is gone, and the wreckage says a lot about why brain diseases remain pharma's hardest problem.